Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 22

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
)(3,562,766)Foreign currency translation adjustments— — — 6,860 — 6,860 Balance at September 30, 202513,929,502 $1,393 $190,499,662 $(395,966)$(187,247,186)$2,857,903 

See accompanying notes.

3

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

Nine Months Ended September 30, 2024AdditionalAccumulatedotherTotalCommon stockpaid-incomprehensiveAccumulatedstockholders'SharesAmountcapitallossdeficitdeficitBalance at December 31, 20238,331,161 $833 $166,548,454 $(360,896)$(171,236,031)$(5,047,640)Stock-based compensation— — 627,700 — — 627,700 Issuance of common stock, net of issuance costs50,664 5 215,108 — — 215,113 Net loss— — — — (6,755,356)(6,755,356)Foreign currency translation adjustments— — — (39,227)— (39,227)Balance at March 31, 20248,381,825 $838 $167,391,262 $(400,123)$(177,991,387)$(10,999,410)Stock-based compensation— — 562,719 — — 562,719 Issuance of common stock, net of issuance costs42,583 4 182,974 — — 182,978 Reverse stock split adjustment121,953 12 (12)— — — Net income— — — — 12,910,656 12,910,656 Foreign currency translation adjustments— — — 14,563 — 14,563 Balance at June 30, 20248,546,361 $854 $168,136,943 $(385,560)$(165,080,731)$2,671,506 Stock-based compensation— — 523,577 — — 523,577 Reverse stock split adjustment3 — — — — — Net income